Section 28A: Interpretation of Part IIA

28A. Interpretation of Part IIA In this Part – “authorised patient” means a patient who is, pursuant to section 28F, issued with a prescription to be treated with medicinal cannabis; “authorised pharmacist” means a Government pharmacist who – (a) has successfully completed a training course, as approved by the Ministry, on the therapeutic use of medicinal cannabis; and (b) is authorised, in writing, by the Ministry to handle and dispense medicinal cannabis; “authorised specialist” means a specialist who – (a) is registered as such under section 20 of the Medical Council Act; Acts 2022 535 (b) has successfully completed a training course, as approved by the Ministry, on the therapeutic use of medicinal cannabis; and (c) is authorised, in writing, by the Ministry to make a request for, and to issue a prescription to, a patient to be treated with medicinal cannabis; “specific therapeutic conditions” – (a) means – (i) spasticity, associated with multiple sclerosis, that has failed to respond to conventional treatment; (ii) severe refractory epilepsy that has failed to respond to conventional anti-convulsant treatment; (iii) intractable nausea and vomiting, associated with chemotherapy, that has failed to respond to conventional anti-emetic treatment; or (iv) severe intractable pain that has failed to respond to conventional treatment; and (b) includes such other therapeutic conditions as may be authorised by the Medicinal Cannabis Therapeutic Committee based on therapeutic evidence.